Zacks: Analysts Anticipate Fibrocell Science Inc (FCSC) to Post -$0.83 EPS
Equities analysts expect that Fibrocell Science Inc (NASDAQ:FCSC) will post earnings of ($0.83) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Fibrocell Science’s earnings. Fibrocell Science posted earnings per share of ($1.70) in the same quarter last year, which indicates a positive year-over-year growth rate of 51.2%. The firm is expected to announce its next earnings report on Monday, November 12th.
According to Zacks, analysts expect that Fibrocell Science will report full year earnings of ($3.31) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($3.01) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Fibrocell Science.
Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.50).
FCSC opened at $2.16 on Wednesday. The stock has a market cap of $18.71 million, a P/E ratio of -0.26 and a beta of 0.69. Fibrocell Science has a fifty-two week low of $1.75 and a fifty-two week high of $18.90.
An institutional investor recently raised its position in Fibrocell Science stock. Point72 Asset Management L.P. boosted its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 100.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 400,000 shares of the company’s stock after buying an additional 200,000 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.41% of Fibrocell Science worth $236,000 as of its most recent SEC filing. 25.79% of the stock is owned by hedge funds and other institutional investors.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Recommended Story: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.